Skip to main content

Table 4 Univariate survival analysis for entire cohort

From: Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population

Characteristic

Overall survival

Progression-free survival

HR

95% CI

p-value

HR

95% CI

p-value

Age ≥ 60 years

4.30

1.92 to 9.63

0.0004

2.61

1.40 to 4.87

0.0025

Sex (male)

1.00

0.44 to 2.29

0.9994

0.94

0.50 to 1.77

0.8554

Ethnicity (Chinese)

0.73

0.29 to 1.87

0.5160

0.86

0.42 to 1.75

0.6750

Smoking history present

1.01

0.30 to 3.38

0.9910

0.73

0.30 to 1.80

0.4964

B-symptoms present

1.93

0.87 to 4.29

0.1061

1.26

0.68 to 2.34

0.4711

ECOG 1–4

2.53

1.12 to 5.71

0.0261

1.84

0.97 to 3.48

0.0608

Bulky disease > 10 cm

0.56

0.14 to 2.34

0.4300

0.71

0.26 to 1.96

0.5136

sMIPI intermediate-high

1.50

0.68 to 3.32

0.3184

1.43

0.79 to 2.60

0.2423

Ann Arbor stage 3–4

0.60

0.21 to 1.72

0.3398

1.22

0.55 to 2.72

0.6314

Lymph node involvement ≥ 4

0.47

0.21 to 1.03

0.0598

0.99

0.55 to 1.78

0.9649

Extra-nodal involvement

0.52

0.17 to 1.56

0.2454

0.73

0.31 to 1.70

0.4621

Bone marrow involvement

0.46

0.20 to 1.03

0.0586

0.59

0.32 to 1.11

0.1029

Spleen involvement

0.50

0.22 to 1.16

0.1081

0.91

0.48 to 1.73

0.7723

Serum LDH elevated

1.02

0.46 to 2.27

0.9529

1.59

0.88 to 2.87

0.1240

Hb ≤ 12.4 g/dL

3.05

1.42 to 6.57

0.0044

2.02

1.12 to 3.64

0.0190

WBC > 10 * 109 cells/L

1.54

0.64 to 3.68

0.3311

1.24

0.64 to 2.40

0.5147

Albumin < 35 g/L

1.71

0.70 to 4.17

0.2412

3.11

1.48 to 6.51

0.0026

  1. Abbreviations: ECOG Eastern Cooperative Oncology Group